BNFC June 2024 Update

This update contains 4 significant changes, 5 dose changes, 5 new monographs and 1 deleted monograph.

Significant Changes:

• Borderline substances: products suitable for conditions requiring a ketogenic diet have been moved to a new section called Ketogenic diet.
• Diabetic hyperglycaemic emergencies: updated guidance for management of individuals aged 16-18 years.
• Gentamicin : removal of indication and dose for treatment of Pseudomonal lung infection in cystic fibrosis.
• Meningococcal vaccines: updated guidance for immunisation.

Dose Changes:

• Amikacin [update to dosing for pulmonary infection with Pseudomonas aeruginosa in cystic fibrosis].
• Bexsero® ( meningococcal group B vaccine (rDNA, component, adsorbed) ) [update to dosing].
• Cyanocobalamin [update to dosing].
• Haemophilus influenzae type b with meningococcal group C vaccine [update to dosing].
• Meningococcal groups A with C and W135 and Y vaccine [update to dosing].

New Monographs:

• Adacel® [diphtheria with tetanus and pertussis vaccine].
• Entresto® [sacubitril with valsartan].
• Opdivo® [nivolumab].
• Opdualag® [nivolumab with relatlimab].
• Velsipity® [etrasimod].

Deleted Monographs:

• Artenimol with piperaquine phosphate.”